Polyrizon Ltd. (PLRZ), a biotech company, announced today that it has entered into a manufacturing agreement with Eurofins Contract Development & Manufacturing Organization (CDMO) Amatsiaquitaine S.A.S, a Europe-based Good Manufacturing Practice manufacturer.
The agreement enables Polyrizon, a company specializing in intranasal hydrogel, to secure a reliable source of clinical trial material for trial initiation of PL-14.
The clinical trial will evaluate PL-14 as an allergy blocker for developing nasal sprays and is expected to commence in 2025.
Currently, PLRZ is trading higher at $1.23, up by 31.23 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.